Induced Pluripotent Stem Cell (iPS Cells) - Content Archive

Cartherics and Catalent Expand Commercial License Agreement

April 29, 2026 By BioInformant Team Leave a Comment

MELBOURNE, Australia & TAMPA, FL – Cartherics Pty Ltd, a biotech company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, has announced an enhanced partnership.

The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics’ mission to develop immune cell therapy products for the treatment of cancer and endometriosis. [Read more…]

South Korean-based “iPS Bio” Establishes Japanese Subsidiary, Deepening Ties to Japan’s iPSC Ecosystem

April 24, 2026 By BioInformant Team Leave a Comment

A South Korea–based regenerative medicine company, iPS Bio, Inc., is accelerating its international footprint with the establishment of a new Japanese subsidiary in Yokohama, Kanagawa Prefecture. The move reflects a broader trend of cross-border collaboration in the induced pluripotent stem cell (iPSC) sector, particularly between leading innovation hubs in East Asia. [Read more…]

Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges

April 16, 2026 By BioInformant Team Leave a Comment

Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies — directly applicable to biotech and pharma iPSC programs.

Toulouse, 2026 April 16^th– Scale-up remains one of the most critical unsolved challenges in iPSC-derived cell therapy. Despite strong clinical promise, most manufacturing processes today can only supply material for a very limited number of patients — a bottleneck that limits clinical progression and commercial viability across the field. [Read more…]

iPSC Therapies Make History: Japan Authorizes World’s First Two iPSC-based Cell Therapies

April 3, 2026 By BioInformant Team Leave a Comment

Recently, the world witnessed the approval of the world’s first two iPSC-derived medicines, as Japan’s health ministry panel authorized their commercialization on February 19, 2026. The approved therapies are ReHeart, developed by Cuorips Inc., a regenerative medicine company spun out of research at Osaka University, and Amchepry, developed by Sumitomo Pharma Co., Ltd. in collaboration with Racthera Inc. [Read more…]

Key Events in the Evolution of iPSC Products that You Need to Know

April 3, 2026 By Cade Hildreth, Founder & President Leave a Comment

Developing induced pluripotent stem cell (iPSC) products requires a thorough understanding of the evolution of iPSC research advances. Because the cell type was recently discovered in 2006, the following presents a decade-long timeline of key events in the discovery and evolution of induced pluripotent stem cell products.

The research events below drove forward interest in the use of iPSCs for basic research and clinical applications. These events are the reason that the first clinical trial involving the implantation of iPSCs into humans was initiated in 2013, to assess the capacity of the cell type to treat loss of eyesight due to macular degeneration.

For this reason, stem cell company executives and stem cell industry investors will be better suited to make future decisions about iPSC products if they have a historical understanding of the recent past and the rate at which research advances with the cell type accelerated. [Read more…]